Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
Disney Plans TV Restructuring With Hundreds of Layoffs 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Add as a preferred source on Google
UTRECHT, The Netherlands, Aug. 09, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 [email protected] Investors: Kimberly Minarovich +1 646 368 8014 [email protected]
